APOE and early-onset autosomal dominant Alzheimer disease: Given the link between these APOE genetic variations and Alzheimer's Disease (31), Companies/laboratories producing nutrigenetic tests that include APOE (rs429358 and rs7412) as it relates to plasma TG responsiveness to EPA and/or DHA, and HCPs offering such tests to patients must comply with the regulations relevant to their territory of practice, while also considering any ethical and legal implications of this test.